Medicure Inc (TSXV:MPH)(OTC:MCUJF), a pharmaceutical company, announced yesterday its financial results for the quarter ended 30 June 2019.
The company reported adjusted EBITDA for the quarter ended 30 June 2019 at USD103,000 compared to adjusted EBITDA of USD882,000 for the quarter ended 30 June 2018.
The firm posted net loss for the quarter ended 30 June 2019 at USD957,000 compared to net income of USD1.6m for the quarter ended 30 June 2018.
Net loss for the six months ended 30 June 2019 was USD3.7m or USD0.24 per share. This compares to net income of USD3.0m or USD0.19 per share for the six months ended 30 June 2018.
Abbott announces quarterly common dividend
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption